

Liza M. Walsh
Selina M. Ellis
Hector D. Ruiz
Christine P. Clark
WALSH PIZZI O'REILLY FALANGA LLP
Three Gateway Center
100 Mulberry Street, 15th Floor
Newark, NJ 07102
(973) 757-1100

Attorneys for Plaintiffs

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

TEVA BRANDED PHARMACEUTICAL
PRODUCTS R&D, INC., and
NORTON (WATERFORD) LTD.,

Plaintiffs,

v.

CIPLA USA, INC. and CIPLA LTD.,

Defendants.

Civil Action No. 2:24-cv-00909
(SRC)(MAH)

TEVA BRANDED PHARMACEUTICAL
PRODUCTS R&D, INC., and
NORTON (WATERFORD) LTD.,

Plaintiffs,

v.

CIPLA USA, INC. and CIPLA LTD.,

Defendants.

Civil Action No. 2:24-cv-05856
(SRC)(MAH)

STIPULATION AND ~~PROPOSED~~ ORDER

Plaintiffs Teva Branded Pharmaceutical Products R&D, Inc. (“Teva”) and Norton (Waterford) Ltd. (“Norton”) (collectively, “Teva”) and Defendants Cipla USA, Inc. and Cipla Ltd. (collectively, “Cipla”), by their undersigned counsel, stipulate and agree as follows:

WHEREAS, after receiving Notice of Paragraph IV Certifications from Cipla, which seeks regulatory approval of Cipla’s beclomethasone dipropionate metered aerosol inhalation products, Teva filed a Complaint asserting infringement of U.S. Patent Nos. 8,132,712 (the “712 patent”), 8,931,476 (the “476 patent”), 10,022,509 (the “509 patent”), 10,022,510 (the “510 patent”), 10,086,156 (the “156 patent”), 10,561,808 (the “808 patent”), 10,695,512 (the “512 patent”), 10,792,447 (the “447 patent”), 11,395,888 (the “888 patent”), 11,395,889 (the “889 patent”), 11,559,637 (the “637 patent”), and 11,583,643 (the “643 patent”) in Civil Action No. 2:24-cv-00909 (SRC)(MAH) (“the 24-909 Action”), which are listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (“the Orange Book”) in connection with Plaintiffs’ QVAR ReditHaler® (beclomethasone dipropionate, 40 mcg) product pursuant to 21 U.S.C. § 355.

WHEREAS, after receiving additional Notice of Paragraph IV Certifications from Cipla, Teva filed a Complaint asserting infringement of U.S. Patent Nos. 11,793,953 (the “953 patent”), 11,865,247 (the “247 patent”), and 11,896,759 (the “759 patent”) in Civil Action No. 2:24-cv-05856 (SRC)(MAH) (“the 24-5856 Action”), which are listed in the Orange Book in connection with Plaintiffs’ QVAR ReditHaler® (beclomethasone dipropionate, 40 mcg) product pursuant to 21 U.S.C. § 355.

WHEREAS, Teva and Cipla previously stipulated to consolidation of the 24-909 and 24-5856 Actions. *See* C.A. No. 24-909, D.I. 10.

WHEREAS, Cipla's responsive pleadings in the 24-909 and 24-5856 Actions are due on or before June 14, 2024.

WHEREAS, no earlier than June 3, 2024, Teva received a Notice of Paragraph IV Certification from Cipla relating to U.S. Patent No. 11,957,832 (the "'832 patent") in connection with Cipla's efforts to seek regulatory approval of Cipla's beclomethasone dipropionate metered aerosol inhalation products.

NOW THEREFORE, Teva and Cipla hereby stipulate and agree, subject to the approval of the Court, as follows:

1. To conserve judicial resources, Teva and Cipla agree to consolidate the 24-909 and 24-5856 Actions with the forthcoming Complaint relating to Cipla's Notices of Paragraph IV Certification in connection with the '832 patent, for all purposes, including discovery, case management, and trial, subject to further order of the Court.
2. Teva agrees to file the Complaint relating to the '832 patent on or before June 21, 2024.
3. The parties agree that Cipla shall have until July 3, 2024, to file an answer, move or otherwise respond to the above referenced Complaints.

Respectfully submitted,

Dated: June 13, 2024

OF COUNSEL:

David I. Berl
Benjamin M. Greenblum
Elise M. Baumgarten
Kathryn S. Kayali
Ben Picozzi
Ricardo Leyva
Richard Hildreth III
WILLIAMS & CONNOLLY LLP
680 Maine Avenue S.W.
Washington, DC 20024
Tel: (202) 434-5000
dberl@wc.com
bgreenblum@wc.com
ebaumgarten@wc.com
kkayali@wc.com
bpicozzi@wc.com
rleyva@wc.com
rhildreth@wc.com

*Attorneys for Plaintiffs Teva Branded
Pharmaceutical Products R&D, Inc. and Norton
(Waterford) Ltd.*

WALSH PIZZI O'REILLY FALANGA LLP

s/Liza M. Walsh

Liza M. Walsh
Selina M. Ellis
Hector D. Ruiz
Christine P. Clark
WALSH PIZZI O'REILLY FALANGA LLP
100 Mulberry Street, 15th Floor
Newark, New Jersey 07102
Tel: (973) 757-1100
lwalsh@walsh.law
sellis@walsh.law
hruiz@walsh.law
cclark@walsh.law

*Attorneys for Plaintiffs Teva Branded
Pharmaceutical Products R&D, Inc. and Norton
(Waterford) Ltd.*

K&L GATES LLP

s/Loly G. Tor

Loly G. Tor (loly.tor@klgates.com)
K&L GATES LLP
One Newark Center, 10th Floor Newark, NJ
07102
(T) 973.848.4026
(F) 973.848.4001

*Attorneys for Defendants Cipla USA, Inc. and
Cipla Ltd.*

SO ORDERED

s/Michael A. Hammer

Michael A. Hammer, U.S.M.J.

Date: 6/13/2024